m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02162)
Name
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
Synonyms
CHEMBL1171972; 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C11H9Cl2NO2S2
InChI
1S/C11H9Cl2NO2S2/c1-7-2-4-8(5-3-7)14-18(15,16)9-6-10(12)17-11(9)13/h2-6,14H,1H3
InChIKey
OQWXAWNHXDPWGS-UHFFFAOYSA-N
PubChem CID
49798484
TTD Drug ID
D06WUE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin A2 (CCNA2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin A2 (CCNA2) is a therapeutic target for 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide through regulating the expression of Cyclin A2 (CCNA2). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin A2 (CCNA2) is a therapeutic target for 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide through regulating the expression of Cyclin A2 (CCNA2). [1], [2]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. doi: 10.1021/jm000271k.